AKBA Earnings Date: Nov 9, 2026 (Estimated) — Akebia Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is AKBA's next earnings date?
Akebia Therapeutics, Inc. (AKBA) is expected to report Q3 2026 earnings on Monday, November 9, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.04 on revenue of $46.9M.
How did AKBA do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), Akebia Therapeutics, Inc. posted EPS of -$0.03 versus the -$0.04 estimate, a beat of 0.0%. Revenue was $49.1M against a $48.9M estimate. The stock's 1-day post-earnings move was -26.0%.
How much does AKBA stock move after earnings?
AKBA beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 15.2% (up or down) in the day after earnings.
About Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical Co. Ltd. for vadadustat's development and commercialization across major regions including the United States, European Union, Russia, China, Australia, Canada, and the Middle East; with Mitsubishi Tanabe Pharma Corporation for vadadustat in Japan and other Asian territories; and a research and licensing deal with Janssen Pharmaceutica NV pertaining to hypoxia-inducible factor prolyl hydroxylase targeted compounds globally.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | -0.04 | -0.03 | +0.00% | $49.1M | ✅ Beat | -26.02% | -30.76% | -23.78% |
| 2026-05-07 | Q1 2026 | -0.01 | -0.03 | -200.00% | $53.5M | ❌ Miss | -20.27% | -20.27% | -36.80% |
| 2026-02-26 | Q4 2025 | -0.05 | -0.05 | +0.00% | $57.6M | ➖ Inline | +9.09% | +3.31% | +14.88% |
| 2025-11-10 | Q3 2025 | -0.02 | 0.00 | +100.00% | $58.8M | ✅ Beat | -18.14% | -18.14% | -22.55% |
| 2025-03-13 | Q4 2024 | -0.08 | -0.10 | -25.00% | $46.5M | ❌ Miss | -12.44% | +47.15% | -19.69% |
| 2024-11-07 | Q3 2024 | -0.06 | -0.10 | -66.67% | $37.4M | ❌ Miss | -6.75% | -4.00% | +2.50% |
| 2024-05-09 | Q1 2024 | -0.08 | -0.09 | -12.50% | $32.6M | ❌ Miss | -5.00% | -15.71% | -24.29% |
| 2024-03-14 | Q4 2023 | -0.04 | 0.00 | +100.00% | $56.2M | ✅ Beat | +24.09% | +48.91% | +1.46% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $3.0M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| License, Collaboration And Other Revenue | 79.8% | $2.4M | — | — | — | — | — |
| Supply Agreement | 16.9% | $500K | — | — | — | — | — |
| License Collaboration And Other Revenue, Royalties | 3.4% | $100K | — | — | — | — | — |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.